Caladrius Biosciences to Present at the BIO Investor Forum Digital
Caladrius Biosciences (Nasdaq: CLBS) has announced that its CEO, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum from October 13-15, 2020. This presentation will be accessible on demand for attendees. Caladrius focuses on cellular therapies aimed at reversing diseases, with current candidates including CLBS119 for lung repair in severe COVID-19 cases and treatments for ischemic diseases. The company is advancing innovative therapies for conditions like critical limb ischemia and coronary microvascular dysfunction.
- None.
- None.
BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who have experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
FAQ
What is the purpose of Caladrius Biosciences' participation in the BIO Investor Forum?
What are the key product candidates of Caladrius Biosciences?
When does Caladrius plan to initiate a clinical trial for CLBS119?
What designation has HONEDRA received from Japan?
What is the significance of the BIO Investor Forum?
